In the News
September 27, 2012 | Fierce Biotech
10 Next-gen Biologics Platforms to Watch
"First-generation biologics took a long time to reach their commercial potential, with many setbacks along the way. The test of faith among biotech companies such as Amgen, Genentech and Biogen Idec paid off with blockbuster products that brought game-changing drugs to patients and turned those once-small players into giants....
MacroGenic's Dual-Affinity Re-Targeting (DART)
Now, second-generation platforms are looking to make the same dramatic impact on patient care as first-generation monoclonal antibodies. In some cases, companies developing these platforms are taking the risk that their products are superior to first-generation products. They believe that theirs, for instance, could be more potent against disease targets--including having the ability to treat more than one aspect of a disease simultaneously--or have other positive attributes, including better and cheaper production processes or fewer side effects....
technology can target multiple disease-causing cells or different disease-causing pathways with one antibody, part of the new generation of bispecific antibodies."
Link to full story
« back to news list
2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All